Phase 3 Heal-MI Study Published
- haraldkattnig5
- Jul 4, 2023
- 2 min read
Updated: Mar 6, 2025
San Francisco, July 5, 2023 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced that its global pivotal Phase 3 HEAL-MI trial was published at clinicaltrials.gov.
Recardio today announced that its global pivotal Phase 3 HEAL-MI trial was published in clinicaltrials.gov:
The global pivotal Phase 3 HEAL-MI trial for Recardio’s lead therapeutic candidate, Dutogliptin, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack, will start in September 2023 with first patient enrollment planned in the fourth quarter of 2023.
“The coming years will be exciting for Recardio as we are starting our global pivotal Phase 3 trial with Dutogliptin in AMI, one of the most promising indications from our cardiovascular platform technology” said Dr. Roman Schenk, Recardio’s founder, President and Executive Chairman.
Recardio’s non-invasive regenerative approach can potentially play a significant role in improving the survival rate and quality of life for patients who experience a heart attack, as well as in various other cardiovascular diseases.
About Recardio
Recardio Inc. is a late clinical-stage life science company focused on developing therapies for cardiovascular and other diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines critical for cardiac regeneration, resulting in healing cardiac tissue after an injury.
Recardio has received FDA and EMA clearance for a global pivotal phase III HEAL-MI clinical trial in acute myocardial infarction. This trial is planned to initiate in 2025 and will serve as the basis to apply for market authorization in major global markets. Recardio plans to fully develop its therapeutic platform for patients with various cardiovascular diseases. The company is headquartered in San Francisco, California, with operations in both the US and Europe.
For more information, visit: www.recardio.eu or contact pr@recardio.eu
